

# Jasmanda Wu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2082171/publications.pdf>

Version: 2024-02-01

10  
papers

116  
citations

1478505

6  
h-index

1474206

9  
g-index

10  
all docs

10  
docs citations

10  
times ranked

215  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes in highâ€hypoglycaemiaâ€risk patients with type 2 diabetes switching to insulin glargine 300ÂU/mL versus a firstâ€generation basal insulin analogue in the United States : Results from the DELIVER High Risk realâ€world study. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00306.	2.4	5
2	How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 <sc>U/mL</sc> in a realâ€world setting?. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 838-843.	4.4	5
3	Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study. <i>Advances in Therapy</i> , 2020, 37, 3863-3877.	2.9	7
4	Early hypoglycaemia and adherence after basal insulin initiation in a nationally representative sample of Medicare beneficiaries with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2486-2495.	4.4	10
5	Switching to insulin glargine 300 units/mL in realâ€world older patients with type 2 diabetes (DELIVER 3). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2384-2393.	4.4	25
6	Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER NaÃve D realâ€world study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2123-2132.	4.4	24
7	The US Food and Drug Administrationâ€™s Risk Evaluation and Mitigation Strategy (REMS) Program â€“ Current Status and Future Direction. <i>Clinical Therapeutics</i> , 2016, 38, 2526-2532.	2.5	17
8	Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm. <i>Cancer Epidemiology</i> , 2015, 39, 242-249.	1.9	16
9	Assessment of Dronedarone Utilization Using US Claims Databases. <i>Clinical Therapeutics</i> , 2014, 36, 264-272.e2.	2.5	7
10	Abstract 18020: Identifying Hospitalizations Related to Heart Failure in Dronedarone Users Who Are Supplementary Medicare Beneficiaries. <i>Circulation</i> , 2014, 130, .	1.6	0